Wang Yao, Liang Lubiao, Tang Yang, Song Yongxiang, Xu Gang, Ke Xixian, Chen Cheng
Department of Thoracic Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.
Oncol Lett. 2025 Apr 28;29(6):317. doi: 10.3892/ol.2025.15063. eCollection 2025 Jun.
The majority of stage III non-small cell lung cancer (NSCLC) is unresectable. However, effective treatment may enable patients to transition to resectable NSCLC, thereby extending the progression-free survival time. The current study presents the case of a female patient with stage IIIC unresectable lung cancer. The patient received icotinib followed by neoadjuvant aumolertinib, resulting in significant tumor shrinkage and downstaging to meet resectability criteria. Despite ~16 months of targeted therapy, including resistance to both first- and third-generation epidermal growth factor receptor-tyrosine kinase inhibitors, the patient achieved partial remission (PR) and became a candidate for surgical intervention. The patient was successfully transitioned from inoperable stage IIIC cancer to surgically resectable stage IB (ypT2N0M0). Postoperatively, the patient received aumerotinib as adjuvant therapy and is currently undergoing follow-up visits without evidence of recurrence or metastasis. The present findings provide novel insights into potential treatment choices for patients with inoperable stage IIIC NSCLC, emphasizing the possibility of achieving PR and undergoing surgery despite drug resistance. However, individual variations in such cases necessitate further research and validation before this approach can be widely implemented.
大多数Ⅲ期非小细胞肺癌（NSCLC）无法切除。然而，有效的治疗可能使患者转变为可切除的NSCLC，从而延长无进展生存时间。本研究介绍了一名患有不可切除的ⅢC期肺癌女性患者的病例。该患者先接受了埃克替尼治疗，随后接受了新辅助奥莫替尼治疗，导致肿瘤显著缩小并降期至符合可切除标准。尽管进行了约16个月的靶向治疗，包括对第一代和第三代表皮生长因子受体酪氨酸激酶抑制剂均耐药，但该患者仍实现了部分缓解（PR），并成为手术干预的候选者。该患者成功地从不可手术的ⅢC期癌症转变为可手术切除的ⅠB期（ypT2N0M0）。术后，患者接受奥莫替尼作为辅助治疗，目前正在接受随访，无复发或转移迹象。本研究结果为不可手术的ⅢC期NSCLC患者的潜在治疗选择提供了新的见解，强调了尽管存在耐药性，但仍有可能实现PR并接受手术。然而，在此方法能够广泛应用之前，此类病例的个体差异需要进一步研究和验证。
